Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548083 | 0.89 | PARP10 (0.43) | CHEK2MEN1KMT2AICAM1SELE | |
| SCHEMBL15045551 | 0.89 | GPR17 (0.46) | CHEK2KMT2ARHEBPOLB | |
| SCHEMBL12651132 | 0.86 | GPR17 (0.34) | CHEK2KMT2ACYP1A2POLBCYP3A4 | |
| SCHEMBL3206966 | 0.86 | MEN1 (0.42) | MEN1KMT2ANPC1CYP1A2CYP3A4 | |
| SCHEMBL1548446 | 0.85 | GRM5 (0.36) | CCNCCDK8KDRBRAF | |
| SCHEMBL1548315 | 0.85 | ALDH1A1 (0.51) | MEN1KMT2AICAM1SELECCNC | |
| SCHEMBL1548263 | 0.84 | MEN1 (0.45) | CHEK2MEN1KMT2ANPC1TSHR | |
| SCHEMBL3212694 | 0.84 | MAP2 (0.42) | CHEK2NPC1ALOX5HDAC1 | |
| SCHEMBL1547971 | 0.82 | KDM4E (0.51) | MEN1KMT2APOLBTSHRKDM4E | |
| SCHEMBL1548405 | 0.81 | MEN1 (0.38) | MEN1KMT2ANPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314575-B1 | NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-06-19 | — | — | EP | claimed |
| US-8445529-B2 | Indole derivative having, carbamoyl group, ureido group and substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | claimed |
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | claimed |
| EP-2314575-B1 | NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-2314575-B1 | NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8445529-B2 | Indole derivative having, carbamoyl group, ureido group and substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445529-B2 | Indole derivative having, carbamoyl group, ureido group and substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2314575-A1 | NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDE GROUP AND SUBSTITUTED OXY GROUP | Santen Pharmaceutical Co., Ltd (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2314575-A1 | NOVEL INDOLE DERIVATIVE HAVING CARBAMOYL GROUP, UREIDE GROUP AND SUBSTITUTED OXY GROUP | Santen Pharmaceutical Co., Ltd (JP) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124668-A1 | NOVEL INDOLE DERIVATIVE HAVING, CARBAMOYL GROUP, UREIDO GROUP AND SUBSTITUTED OXY GROUP | IKBKB, CHUK, RELA | CHEK2 923/4885MEN1 4020/4885KMT2A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.